All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Rhes (RASD2) is a gene encoding for a GTP-binding protein highly enriched in the corpus striatum \[[@pone.0181677.ref001]--[@pone.0181677.ref003]\], and developmentally regulated by thyroid hormones \[[@pone.0181677.ref004], [@pone.0181677.ref005]\]. To a lesser extent, also dopamine regulates Rhes mRNA levels in adult rat striatum \[[@pone.0181677.ref006], [@pone.0181677.ref007]\]. Neuroanatomical observations, performed on human and rodent brains, showed that Rhes mRNA is localized in virtually all dopamine D1 and D2 receptor (R)-bearing medium-sized spiny neurons, as well as in cholinergic interneurons of the caudate-putamen \[[@pone.0181677.ref008]--[@pone.0181677.ref010]\]. Rhes transcript is also expressed in rodent and human hippocampus, within the granule cell layer of the dentate gyrus and pyramidal cell layer of Ammon's horn \[[@pone.0181677.ref001], [@pone.0181677.ref002], [@pone.0181677.ref007], [@pone.0181677.ref008], [@pone.0181677.ref011]\]. Interestingly, in mice Rhes mRNA-positive neurons are distributed within the cortical layers II-III, while in the human cortex Rhes transcript is detected throughout layers II--VI, with a distinctive higher expression in layer V \[[@pone.0181677.ref012]\]. From a functional perspective, Rhes modulates striatal dopamine D1R and D2R transmission, by influencing cAMP/PKA and AKT pathways \[[@pone.0181677.ref008]--[@pone.0181677.ref011], [@pone.0181677.ref013]--[@pone.0181677.ref016]\]. Rhes also binds to and activates mTORC1 signalling in the striatum, which is known to influence the expression of L-DOPA-induced dyskinesia (LID) in rodent PD models \[[@pone.0181677.ref017], [@pone.0181677.ref018]\]. Accordingly, we recently found that dopamine-depleted Rhes knockout mice show a significant LID reduction, while the beneficial anti-akinetic effect of L-DOPA is preserved \[[@pone.0181677.ref019], [@pone.0181677.ref020]\]. Strikingly, Snyder and colleagues reported that Rhes acts as a unique striatal E3 ligase for mutant huntingtin sumoylation, a biochemical process that causes cellular neurotoxicity in Huntington's disease \[[@pone.0181677.ref021]--[@pone.0181677.ref026]\]. Thus, in addition to its involvement in PD-related processes, Rhes is currently considered to be a molecular determinant in cellular and behavioural Huntington's disease-associated phenotypes \[[@pone.0181677.ref027]\]. Though a putative link between Rhes and neurodegenerative disorders has been established, this G-protein, by regulating AKT and cAMP/PKA signalling, might also play a role in biochemical pathways in the brain of BD and SCZ patients \[[@pone.0181677.ref028]--[@pone.0181677.ref030]\]. Accordingly, a variant of the Rhes gene (rs736212) has been associated with a sub-group of patients with SCZ \[[@pone.0181677.ref031]\], while another polymorphism (rs6518956) relevant for SCZ correlates with fronto-striatal endophenotypes in healthy subjects \[[@pone.0181677.ref012]\]. Consistent with its potential role in psychiatric diseases, Rhes also interacts with striatal proteins, such as PDE2A (phosphodiesterase 2A) and LRRC7 (leucine-rich repeat--containing 7), reported to be associated with major depression and BD \[[@pone.0181677.ref032]\]. Therefore, in order to investigate the possible alteration of Rhes mRNA expression in neurodegenerative and psychiatric disorders, we evaluated whether its transcript levels might be affected by the diagnosis of PD, SCZ and BD. To further dissect whether Rhes gene expression might be influenced by the dopamine denervation in an experimental non-human primate model of PD, we also evaluated striatal levels of Rhes mRNA in *Macaca Mulatta*, treated with MPTP.

Materials and methods {#sec002}
=====================

All human tissue collection and processing was carried out in accordance with the declaration of Helsinki. In Italy there is no law regulating the use of biological samples obtained from internationally recognized brain banks. Therefore, because our study did not involve pharmacological research, which is regulated in Italy, ethics committee approval was not required.

Non-human primate studies were carried out in accordance with European Communities Council Directive (2010/63/EU) for care of laboratory animals in an AAALAC-accredited facility following acceptance of study design by the Institute of Lab Animal Science IACUC (Chinese Academy of Medical Sciences, Beijing, China).

Human tissue collection {#sec003}
-----------------------

Putamen samples of normal controls and PD patients were obtained from the Harvard Brain Tissue Resource Center (HBTRC; <http://www.brainbank.mclean.org/>). The clinical and neuropathological criteria for a diagnosis of PD are summarized in [Table 1](#pone.0181677.t001){ref-type="table"}. Dorsolateral prefrontal cortex and hippocampus samples of patients with SCZ and non-psychiatric controls were obtained from The Human Brain and Spinal Fluid Resource Center-Los Angeles (HBSFRC). Prefrontal cortex and putamen samples of patients with SCZ and non-psychiatric controls were obtained from MRC London Neurodegenerative Diseases Brain Bank (MRC-LNDBB). Anterior cingulate cortex samples of patients with SCZ, BD, and non-psychiatric controls, were donated by The Stanley Medical Research Institute (SMRI) brain collection. SCZ and BD diagnoses were established according to DSM IV criteria (see [Table 2](#pone.0181677.t002){ref-type="table"}). For more information about medication of psychiatric patients see [S1](#pone.0181677.s001){ref-type="supplementary-material"} and [S2](#pone.0181677.s002){ref-type="supplementary-material"} Tables. All human data were anonymized.

10.1371/journal.pone.0181677.t001

###### Demographic table of PD brain samples from the Harvard Tissue Resource Center.

![](pone.0181677.t001){#pone.0181677.t001g}

  ID                                   Diagnostic group   Age (years)   PMI (hours)   Accumulated lifetime L-dopa (g)   Treatment duration (y)   Average L-dopa per year treated (g)   Years diagnosed   Neurofibrillary degeneration (Braak Stage)   Cause of death
  ------------------------------------ ------------------ ------------- ------------- --------------------------------- ------------------------ ------------------------------------- ----------------- -------------------------------------------- ---------------------------------------
  1                                    NC                 70            14.3                                                                                                                                                                          myocardial infarction
  2                                    NC                 71            14.07                                                                                                                                                                         Unknown
  3                                    NC                 72            21.62                                                                                                                                                                         myocardial infarction
  4                                    NC                 72            18.25                                                                                                                                                                         cardiac Ischemia
  5                                    NC                 73            19.42                                                                                                                                                                         chronic obstructive pulmonary disease
  6                                    NC                 73            12                                                                                                                                                                            Cancer
  7                                    NC                 73            7.58                                                                                                                                                                          cardiac Arrest
  8                                    NC                 74            22.5                                                                                                                                                                          chronic obstructive pulmonary disease
  9                                    NC                 74            14.33                                                                                                                                                                         myocardial infarction
  10                                   NC                 74            18.58                                                                                                                                                                         myocardial infarction
  11                                   NC                 76            21.25                                                                                                                                                                         cardiopulmonary arrest
  12                                   NC                 77            25.23                                                                                                                                                                         myocardial infarction
  13                                   NC                 79            20.5                                                                                                                                                                          chronic obstructive pulmonary disease
  14                                   NC                 79            20.81                                                                                                                                                                         motor vehicle accident
  15                                   NC                 82            14.33                                                                                                                                                                         liver cancer
  n = 15 (mean±SEM)                    74.87±0.804        17.94±1.194                                                                                                                                                                                 
  16                                   DYS                64            11.4          1,971                             11                       179                                   11                4                                            cardiopulmonary arrest
  17                                   DYS                71            5             128                               1                        128                                   8                 1                                            cardiopulmonary arrest
  18                                   DYS                73            18            1,074                             4                        234                                   14                2                                            cardiopulmonary arrest
  19                                   DYS                75            13.3          1,752                             8                        219                                   11                1                                            cardiopulmonary arrest
  20                                   DYS                77            20.7          4,663                             18                       267                                   21                3                                            bladder cancer
  21                                   DYS                78            14.5          2,197                             9                        233                                   11                2                                            pneumonia
  22                                   DYS                79            23.4          1,476                             8                        197                                   8                 3                                            cardiopulmonary arrest
  23                                   DYS                81            10.5          1,026                             8                        131                                   13                3                                            cardiopulmonary arrest
  24                                   DYS                87            11.7          2,373                             13                       183                                   13                3                                            cardiopulmonary arrest
  25                                   DYS                88            26.5          1,835                             5                        361                                   10                3                                            anoxic encephalopathy
  n = 10 (mean±SEM)                    77.3±2.3           15.5±2.1      1,850±375.9   8.5±1.5                           213.2±21.6               12±1.2                                2.5±0.3                                                        
  26                                   Non-DYS            71            24.7          3,011                             11                       274                                   11                1                                            pneumonia
  27                                   Non-DYS            75            14.1          1,232                             5                        235                                   12                2                                            PD
  28                                   Non-DYS            75            20            511                               4                        120                                   5                 2                                            liver cancer
  29                                   Non-DYS            75            5.5           905                               6                        156                                   6                 2                                            bladder cancer
  30                                   Non-DYS            75            19.8          584                               4                        146                                   7                 2                                            pneumonia
  31                                   Non-DYS            75            16.5          548                               4                        137                                   12                3                                            colon cancer
  32                                   Non-DYS            75            17.2          219                               2                        110                                   5                 2                                            congestive heart failure
  33                                   Non-DYS            77            15.2          584                               5                        117                                   5                 1                                            bradycardia, heart blockage
  34                                   Non-DYS            77            7.2           143                               1                        101                                   5                 2                                            bladder cancer
  35                                   Non-DYS            79            8.2           892                               6                        150                                   17                2                                            cardiopulmonary arrest
  36                                   Non-DYS            80            20.4          2,473                             8                        297                                   11                4                                            cardiopulmonary arrest, pneumonia
  37                                   Non-DYS            84            19.9          24                                0                        146                                   9                 4                                            myocardial infarction
  n = 12 (mean±SEM)                    76.5±0.9           15.7±1.7      927.2±265.6   4.7±0.9                           165.8±19                 8.7±1.1                               2.2±0.3                                                        
  NC vs PD (DYS+Non-DYS) (*p value*)   0.0672             0.2494                                                                                                                                                                                      
  DYS vs Non- DYS (*p value*)          0.6566             0.8718        0.0408        0.0391                            0.1187                   0.0642                                0.4063                                                         

Abbreviations: NC, non-PD control; DYS, dyskinetic PD; Non-DYS, non-dyskinetic PD; PMI, post-mortem interval; Mann-Whitney U test for DYS vs non-DYS characteristics

10.1371/journal.pone.0181677.t002

###### Demographic table of psychiatric brain samples.
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  ------------------------------------------------------------------------ ------------------------------- ----------------------------- -------------- ---------------- ----------- -----------
  **The Human Brain and Spinal Fluid Resource Center (Los Angeles, CA)**                                                                                                             
                                                                           **NC group**                    **SCZ group**                                                             p value
  n = 20 (median; sum of ranks)                                            n = 20 (median; sum of ranks)                                                                             
  Age                                                                      73.5; 555                       52.5; 265                                                                 \< 0.0001
  PMI (h)                                                                  12.85; 335                      15.25; 485                                                                0.0422
  pH                                                                       6.545; 223.5                    6.5; 182.5                                                                0.3574
  Gender                                                                   16 M, 4 F                       12M, 8 F                                      χ^2^ = 1.905                0.1675
  Diagnosis                                                                                                DSMIV-TR                                                                   
  **MRC London Neurodegenerative Diseases Brain Bank**                                                                                                                               
                                                                           **NC group**                    **SCZ group**                                                             p value
  n = 12 (median; sum of ranks)                                            n = 10 (median; sum of ranks)                                                                             
  Age                                                                      63.5;140.5                      63; 112.5                                                                 0.8836
  PMI (h)                                                                  31.5; 95                        48; 136                                                                   0.0070
  Gender                                                                   6M, 6F                          6M, 4F                                       χ^2^ = 0.2200                0.6390
  Diagnosis                                                                                                DSMIV-TR                                                                   
  **The Stanley Medical Research Institute**                                                                                                                                         
                                                                           **NC group**                    **SCZ group**                 **BD group**                                p value
  n = 32 (median;sum of ranks)                                             n = 36 (median;sum of ranks)    n = 29 (median;sum of raks)                                               
  Age                                                                      44.5; 1109                      43.5; 12.38                                                   NC vs SCZ   0.9586
                                                                           44.5; 963                                                     44; 928                         NC vs BD    0.6799
  PMI (h)                                                                  28; 1059                        30; 1288                                                      NC vs SCZ   0.5803
                                                                           28; 862.5                                                     35; 1029                        NC vs BD    0.0614
  Gender                                                                   23M, 9F                         27M, 9F                       14M, 15F        χ^2^            0.0850      0.7706
  (NC vs SCZ)                                                                                                                                                                        
                                                                                                                                                        χ^2^             3.550       09.55.00
  (NC vs BD)                                                                                                                                                                         
  Diagnosis                                                                                                DSMIV-TR                                                                   
  ------------------------------------------------------------------------ ------------------------------- ----------------------------- -------------- ---------------- ----------- -----------

Abbreviations: NC, non-psychiatric control; SCZ, schizophrenia; BD, bipolar disorder; PMI, postmortem interval; h, hours; M/F, male/female; Mann-Whitney U test for Age and PMI characteristics. Chi-square test for Gender characteristic. DMS, Diagnostic and Statistical Manual of mental disorders

Non-human primates housing {#sec004}
--------------------------

Captive bred female macaques (*Macaca mulatta*, Xierxin, Beijing, PR of China; mean age = 5 ± 1 years; mean weight = 5.3 ± 0.8 kg), were housed in individual primate cages under controlled conditions of humidity (50 ± 5%), temperature (24 ± 1°C), and light (12 h light/12 h dark cycles, time lights on 8:00 am), and allowing visual contacts and interaction with macaques housed in the adjacent cages. Food and water were available ad libitum and animal care was supervised daily by veterinarians skilled in the healthcare and maintenance of non-human primates.

MPTP-treated non-human primate PD model {#sec005}
---------------------------------------

Out of fifteen macaques, five received daily MPTP hydrochloride injections (0.2mg/kg, intravenously) until parkinsonian signs appeared \[[@pone.0181677.ref033]\]. Once PD motor signs were stable, five more animals were treated twice daily with an individually titrated dose of L-DOPA that provided maximum reversal of parkinsonian motor signs (Madopar, L-DOPA/carbidopa, 4:1 ratio; range, 9--17mg/kg). This dose of L-DOPA, defined as 100% dose, was used for chronic L-DOPA treatment, which lasted 4 to 5 months until dyskinesia stabilized. Animals then received L-DOPA twice a week to maintain a consistent level of dyskinesia before acute drug tests were carried out using a within-subject experimental design. The remaining five monkeys were used as control. Killing of animals and processing of tissues were carried out according to a previous protocol \[[@pone.0181677.ref033]\]. Briefly, all the animals were killed by sodium pentobarbital overdose (150 mg/kg, i.v.), and the brains were quickly removed after death. Each brain was bisected along the midline, and the two hemispheres were immediately frozen by immersion in isopentane (-45°C) and then stored at -80°C. Tissue was sectioned coronally at 20 μm in a cryostat at -17°C, thaw-mounted onto gelatin-subbed slides, dried on a slide warmer, and stored at -80°C.

*In situ* hybridization (ISH) {#sec006}
-----------------------------

ISH analysis was performed on coronal sections from adult macaque brains (n = 3 control group), according to a protocol previously described \[[@pone.0181677.ref012]\]. RASD2 cDNA was cloned by PCR using the following primers: forward `5’-TACCAGCTGGACATCCTGG-3’`, reverse `5’-CGTCACCGTACTGCACGG-3’`. RASD2 35S-labelled antisense riboprobe, 433 bp in length (nucleotides 398--830, XM-015150119), was used ISH analysis. Hybridized sections were exposed to Biomax MR X-ray films (Kodak, Rochester, NY) for three days. Images of autoradiography films of radioactive ISH experiments were scanned at a resolution of 4800 dpi and images at high magnification were acquired using bright field light microscopy \[[@pone.0181677.ref034]\].

Quantitative RT-PCR analysis in human *post mortem* brain samples and macaques {#sec007}
------------------------------------------------------------------------------

Total RNAs from the HBSFRC, MRC-LNDBB, and SMRI brain samples were extracted using RNeasy^®^ Mini kit (Quiagen, Hilden, Germany), according to the manufacturer's instructions. We used 0.5 μg of total RNA per sample to synthesize cDNA. Quantitative RT-PCR with Real Time ready catalog Assays (hRhes forward: `GGGAGCCACCACAGACTC` and hRhes reverse: `CTGGACAAAGTCTTCATCATGG`; GAPDH forward: `AGCCACATCGCTCAGACAC` and GAPDH reverse: `GCCCAATACGACCAAATCC`; ACTB forward: `TCCTCCCTGGAGAAGAGCTA` and ACTB reverse: `CGTGGATGCCACAGGACT`; PPIA forward: `TTCATCTGCACTGCCAAGAC` and PPIA reverse: `CACTTTGCCAAACACCACAT`) and LightCycler^®^ 480 Probe Master (Roche Diagnostics, Indianapolis, IN) was performed on a Light Cycler 480 II Real Time PCR system with 96-well format (Roche Diagnostics). All measurements from each subject were performed in duplicate. Rhes transcript quantities were normalized by the geometric mean of three housekeeping genes for analysing samples from MRC-LNDBB and SMRI (ACTB, GAPDH and PPIA), and two for the samples of the HBSFRC (ACTB and PPIA). After total RNA extraction (0.5 μg) from macaque tissue, quantitative Real Time amplifications were performed with LightCycler 480 SYBR Green I Master (Roche Diagnostic), in a LightCycler 480 Real Time thermocycler (Roche). The following protocol was used: 10 s for initial denaturation at 95°C followed by 45 cycles consisting of 10 s at 94°C for denaturation, 10 s at 65°C for annealing, and 6 s for elongation at 72°C temperature. The following primers were used for Rhes cDNA amplification: MmRhes forward: `TAACCGGGAGTCCTTCGATG` and MmRhes reverse: `CCTCAAAGTAGGCGCAGTTC`; Mmb-Actb forward: `CTGTGCTATGTCGCCCTAGA` and Mmb-Actb reverse: `GGAAGGTTGGAAGAGAGCCT`. Rhes transcript quantities were normalized by the geometric mean of three housekeeping genes \[[@pone.0181677.ref012], [@pone.0181677.ref035], [@pone.0181677.ref036]\]: MmPp1a forward: `TGCTGGACCCAACACAAATG` and MmPp1a reverse: `GTCCACAGTCAGCAATGGTG`; MmGAPDH forward: `AGGTCGGAGTCAACGGATTT` and MmGAPDH reverse: `ATCTCGCTCCTGGAAGATGG`. Total RNA (150 ng) was extracted from the Putamen of HBTRC samples using the RNeasy Mini Kit (Qiagen). DNA was eliminated from the sample by treatment with DNase I (New England Biolabs, Ipswich, MA). cDNA was synthesized from 150 ng RNA with the Superscript IV kit and random hexamers (Thermo Fisher Scientific, Waltham, MA). Quantitative Real Time PCR amplifications were performed with KAPA SYBR Fast, with ROX as a loading control (Roche Diagnostics), in the MX3005P thermocycler (Agilent Technologies, Wilmington, DE), under the following cycle conditions: 10 min at 95°C for initial denaturation followed by 40 cycles of 20 s at 95°C for denaturation, 20 s at 60°C for annealing, and 20 s at 74°C for elongation. The following primers were used for Rhes cDNA amplification: hRHES-F: `TCCATCGTGTCTCGCTTCCT` and hRHES-R: `CTCATCGAAGGACTCCCGGT`. Rhes transcript quantities were normalized by the geometric mean of five housekeeping genes \[[@pone.0181677.ref012], [@pone.0181677.ref035], [@pone.0181677.ref036]\]: Human 18s rRNA-F: `ACGGCCGGGGGCATTCGTAT`, Human 18s rRNA-R: `ATCGCCGGTCGGCATCGTTT`; hITM2B-F: `CATTGTTATGCCACCCAGAA`, hITM2B-R: `GCAGTTTGTAAGTTTCCTTGTCA`; hCANX-F: `ACTTGTGTTGATGTCTCGGGC`, hCANX-R: `CGTTTTGGGGTTTTTGTGTCGG`; hActb-F: `AGAGCCTCGCCTTTGCCGATCC`, hActb-R: `CATGCCGGAGCCGTTGTCGAC`; hEIF1-F: `GTGATGACCTGCTTCCTGCT`, hEIF1-R: `CTTGCGTTGGTCACCCTGTA`.

Data were analysed through Kruskal-Wallis test and/or Mann-Whitney U test, by using GraphPad software (La Jolla, CA).

Results {#sec008}
=======

Expression levels of Rhes mRNA in Parkinson's disease, Schizophrenia and Bipolar Disorder human brains {#sec009}
------------------------------------------------------------------------------------------------------

We analysed Rhes mRNA levels, by qPCR analysis, in different cerebral regions of patients affected by PD, SCZ and BD (See Tables [1](#pone.0181677.t001){ref-type="table"} and [2](#pone.0181677.t002){ref-type="table"} for demographic details), obtained from four different human brain banks. Notably, our data showed a significant decrease in Rhes mRNA amount in the putamen of PD patients from the HBTRC, compared to the control group (*P* = 0.0420; Mann-Whitney U test; [Fig 1A](#pone.0181677.g001){ref-type="fig"}). Since PD group consists of dyskinetic and non-dyskinetic patients, we also compared Rhes mRNA levels among these groups. Overall, Kruskal-Wallis analysis revealed a clear trend toward reduction of Rhes expression in both dyskinetic and non-dyskinetic patients, compared to controls (*P* = 0.0634; [Fig 1B](#pone.0181677.g001){ref-type="fig"}).

![Quantitative RT-PCR analysis shows a selective reduction in Rhes mRNA levels in *post- mortem* brain samples of patients with Parkinson's disease.\
(A) Putamen samples of PD patients (n = 22), and non-PD controls (n = 15), from the HBTRC. (B) Putamen samples of non-dyskinetic (n = 12) and dyskinetic (n = 10) patients and non-PD controls, from the HBTRC. (C, D) Dorsolateral prefrontal cortex (C) and hippocampus (D) samples from patients with SCZ (n = 20) and non-psychiatric controls (n = 20), from the HBSFRC. (E) Prefrontal cortex samples of patients with SCZ (n = 16) and non-psychiatric controls (n = 19), from MRC-LNDBB. (F) Putamen samples of patients with SCZ (n = 12) and non-psychiatric controls (n = 11), from MRC-LNDBB. (G, H) Anterior cingulate cortex samples of patients with SCZ (n = 36) (G), BD (n = 29) (H) and non-psychiatric controls (n = 32), from the SMRI. Data were analysed by using Kruskal-Wallis test or Mann-Whitney U test. \* *p*\<0.05, compared to non-pathological control (NC) group. All values are expressed as mean ± SEM.](pone.0181677.g001){#pone.0181677.g001}

Conversely, comparable levels of Rhes mRNA were found between SCZ patients and healthy controls, in both dorsolateral prefrontal cortex (*P* = 0.6783; Mann-Whitney U test; [Fig 1C](#pone.0181677.g001){ref-type="fig"}) and hippocampus (*P* = 0.7632; [Fig 1D](#pone.0181677.g001){ref-type="fig"}) samples from the HBSFRC. Similar results were also obtained in both prefrontal cortex (*P* = 0.4611; Mann-Whitney U test; [Fig 1E](#pone.0181677.g001){ref-type="fig"}) and putamen of SCZ patients (*P* = 0.5254; [Fig 1F](#pone.0181677.g001){ref-type="fig"}) from the MRC-LNDBB. In addition, qPCR analysis in the anterior cingulate cortex of SCZ brains from the SMRI, displayed no difference in Rhes mRNA levels, when compared to non-psychiatric controls (*P* = 0.9246; Mann-Whitney U test; [Fig 1G](#pone.0181677.g001){ref-type="fig"}). Finally, analysis of mRNA levels in the same brain region of patients with BD, obtained from the SMRI, revealed no difference when compared to non-psychiatric controls (*P* = 0.2254; [Fig 1H](#pone.0181677.g001){ref-type="fig"}).

Localization of Rhes mRNA in macaque brain {#sec010}
------------------------------------------

To identify the spatial pattern of Rhes mRNA expression we performed *in situ* hybridization analysis on coronal sections of frozen brains of adult non-human primates, *Macaca Mulatta*. In agreement with previous reports in rodent and human brains \[[@pone.0181677.ref008], [@pone.0181677.ref009], [@pone.0181677.ref012]\], abundant levels of Rhes mRNA were observed in the striatum of macaques ([Fig 2B and 2C](#pone.0181677.g002){ref-type="fig"}; corresponding brain atlas tables are depicted in A and C, respectively). An enriched amount of Rhes transcript was evident along the rostro-caudal extent of the striatum in the caudate nucleus and putamen ([Fig 2B", 2B"', 2D' and 2D"](#pone.0181677.g002){ref-type="fig"}). In addition, consistent with previous observations in human brains \[[@pone.0181677.ref008]\], Rhes mRNA was also expressed in the deep layers of the cerebral cortex ([Fig 2B"' and 2D"](#pone.0181677.g002){ref-type="fig"}), *Cornu Ammonis* (CAM) and in the dentate gyrus (DG) of the *Macaca Mulatta* brain ([Fig 2D"'](#pone.0181677.g002){ref-type="fig"}).

![Rhes mRNA expression in Macaca mulatta adult brain.\
(A, C) Graphic representation of *Macaca mulatta* brain sections examined. Rostro-caudal levels are approximate and sections were obtained from [www.brainmaps.org](http://www.brainmaps.org/) \[[@pone.0181677.ref034]\]. (B, D) Representative images of autoradiographic film of radioactive ISH experiments showing *Rhes* expression along the rostro-caudal extent of *Macaca mulatta adult* brain. Boxed regions in B and D are shown at higher magnification in (B') cortical area 6 of the brain, (D') cortical area 3 of the brain, (B"- B"', D'-D") *caudate nucleus* and *putamen* of striatum, (D"') *cornus Ammoni* and dentate gyrus of hippocampus. Abbreviations: 3: cortical area 3; 6: cortical area 6; CA: *caudate nucleus*; CAM: *Cornus* Ammonis; CC: *corpus callosum*; CL: central lateral nucleus of the thalamus; DG: dentate gyrus; ENT: entorhinal cortex; GP: *globus pallidus*; IC: internal capsule; Ins: insula; LS: *lateral sulcus*; PCS: *precentral sulcus*; PSB: *presubiculum*; Pu: *putamen*; R: *reticular nucleus*; OT: optic tract; SB: *subiculum*. Scale bar: 5 mm (A-B, C-D); 1.75 mm (B'-B"', D'-D"').](pone.0181677.g002){#pone.0181677.g002}

Rhes mRNA expression levels in the brain of MPTP-treated *Macaca Mulatta* {#sec011}
-------------------------------------------------------------------------

After establishing its brain localization in healthy macaques, we analysed the amount of Rhes mRNA in the putamen of monkeys treated with MPTP ([Fig 3A](#pone.0181677.g003){ref-type="fig"}), highly regarded as an experimental model of PD \[[@pone.0181677.ref037]\]. Remarkably, Kruskal-Wallis analysis displayed a significant variation of Rhes transcript levels among control vs MPTP vs MPTP+L-DOPA putamen (*P* = 0.0176; [Fig 3B](#pone.0181677.g003){ref-type="fig"}). In particular, Mann-Whitney test showed a significant downregulation of Rhes mRNA amount in MPTP-treated monkeys (control vs MPTP: *P* = 0.0079), that was normalized after 2-week L-DOPA supplementation (control vs MPTP+L-DOPA: *P* = 0.3095).

![Quantitative RT-PCR analysis shows a selective reduction of Rhes mRNA levels in the MPTP macaque PD model, recovered by L-DOPA treatment.\
(A) Experimental design. (B) Putamen of MPTP (n = 5), MPTP+L-DOPA (n = 5) or control (n = 5) monkey groups. Data were analysed by using the Kruskal-Wallis test, followed by Mann-Whitney U test \*\* *p*\<0.01, compared to control group. All values are expressed as mean ± SEM.](pone.0181677.g003){#pone.0181677.g003}

Discussion {#sec012}
==========

Despite an emerging interest in Rhes as a novel molecular target in striatal neuropathology, the vast majority of studies so far were performed in cell cultures and rodent models \[[@pone.0181677.ref016]\]. Here, we measured *Rhes* mRNA levels in a large group of *post-mortem* samples (about 200), from subjects diagnosed with SCZ, BD, PD or healthy controls, obtained from four different international brain banks. Altogether, our results indicated that Rhes mRNA levels in the putamen, hippocampus, anterior cingulate cortex, frontal and dorsolateral prefrontal cortex of SCZ patients did not significantly differ from those of healthy subjects. Similarly, in the anterior cingulate cortex of individuals suffering from BD, Rhes mRNA expression was comparable to that of non-psychiatric subjects. The lack of significant differences in Rhes mRNA expression between brain samples from controls and psychiatric patients does not rule out a possible influence of previous pharmacological medications. However, preclinical data in rats showed that chronic treatment with eticlopride, a selective D2R blocker, did not alter the striatal expression of this gene \[[@pone.0181677.ref006]\].

In contrast with the findings obtained in SCZ and BD brains, we found a significant reduction of Rhes transcript levels in the *post-mortem* putamen of PD patients. It's worth mentioning that both age and PMI values are comparable between healthy controls and PD patients (NC vs PD: Age, *P* = 0.0672; PMI, *P* = 0.2494, Mann-Whitney U test; for further details, see [Table 1](#pone.0181677.t001){ref-type="table"}), thus suggesting that such a downregulation is most likely associated to the pathological condition, rather than demographic sample features. On the other hand, in line with previous findings \[[@pone.0181677.ref038]\], dyskinetic patients analysed here showed a longer accumulated lifetime L-DOPA (*P* = 0.0408) and duration of L-DOPA treatment (*P* = 0.0391), compared to non-dyskinetic subjects ([Table 1](#pone.0181677.t001){ref-type="table"}).

Consistent with PD patient observations, a similar Rhes mRNA decrease was found also in the putamen of MPTP-treated *Macaca Mulatta*. The overall downregulation of Rhes mRNA levels in the putamen of both patients and the non-human primate model is in agreement with previous findings obtained in the striatum of adult 6-OHDA-lesioned rats \[[@pone.0181677.ref006]\], suggesting that the regulation of Rhes gene expression by dopaminergic innervation is conserved across species. Although the biological role of this regulation is still unknown, the inhibitory influence of Rhes over the striatal dopamine-dependent responses, documented by *in vitro* and *in vivo* studies \[[@pone.0181677.ref009], [@pone.0181677.ref010], [@pone.0181677.ref015]\], let us hypothesize that the decrease of this G-protein may represent an event, up-stream to a complex compensatory process, able to functionally counteract the pathological reduction of dopaminergic innervation. In this view, Rhes could act as a physiological "molecular brake" for the striatal dopaminergic transmission, an idea also supported by the evidence that the lack of this GTPase triggers exaggerated motor responses in Rhes knockout mice, treated with very low doses of the dopamine releaser amphetamine \[[@pone.0181677.ref012]\].

In PD mouse model Rhes enhances L-DOPA-induced dyskinesia (LID), most likely through the activation of mTOR pathway \[[@pone.0181677.ref020]\]. Accordingly, a significant LID reduction has been observed in 6-OHDA-treated Rhes knockout mice \[[@pone.0181677.ref019], [@pone.0181677.ref020]\]. Here, despite the above preclinical observations, we did not find any significant differences in the striatal Rhes mRNA levels between dyskinetic and non-dyskinetic patients. Further studies on a larger cohort of *post-mortem* brains from PD patients with, or without, dyskinesia, are required to clarify this issue.

Notably, we report that the pattern of Rhes mRNA expression in the brain of non-human primates resembles that previously described in humans \[[@pone.0181677.ref008], [@pone.0181677.ref012]\]. Indeed, our observations in adult *Macaca Mulatta* demonstrate a prominent expression of Rhes transcript in the caudate putamen and, to a lesser extent, in the cortex, with a spatial pattern reminiscent to that in human brain \[[@pone.0181677.ref012]\]. Interestingly, while L-DOPA administration to MPTP-treated monkeys normalized striatal Rhes mRNA levels, this effect was not found in L-DOPA-treated PD patients. This discrepancy might be explained by a difference in dopamine levels between PD patients and MPTP-lesioned primates at the time of death or sacrifice, respectively. Indeed, while MPTP-treated macaques were killed 60 min after L-DOPA injection \[[@pone.0181677.ref039]\], the last dose of L-DOPA before death of PD patients was likely further in the past, and might have worn off.

However, whether or not the reported reduction of striatal Rhes mRNA expression in PD patients and MPTP-treated macaques might also reflect a decreased expression of the corresponding protein remains an issue to be addressed in future studies. In this respect, it has been shown that mRNA expression is well correlated with protein levels \[[@pone.0181677.ref040]\], though differentially expressed and highly expressed mRNAs correlate better with their protein product than non-differentially expressed mRNAs \[[@pone.0181677.ref041]\]. This is not surprising, since low expressed mRNAs and proteins have a higher degree of natural and methodological noise \[[@pone.0181677.ref042]\]. Rhes is highly expressed in the putamen which indicates that differences in mRNA will likely be reflected in protein levels. Furthermore, correlations of mRNA and protein in the PD putamen were previously verified for molecules such as alpha-synuclein and adenosine A2A receptors \[[@pone.0181677.ref043], [@pone.0181677.ref044]\].

A further support for a possible link between Rhes and Parkinson's disease comes from recent findings indicating that this small GTPase is also expressed in a subset of tyrosine hydroxylase-positive neurons of the substantia nigra pars compacta, where its genetic ablation enhances vulnerability to age-dependent neuronal death in mutant mice \[[@pone.0181677.ref045]\]. Although the specific mechanism underpinning the relationship between Rhes and the survival of dopaminergic neurons is not clear, previous studies demonstrating its binding to beclin-1 \[[@pone.0181677.ref046]\] suggest a potential involvement of this G protein in cellular events implicated in neurodegeneration.

In conclusion, the present data obtained in both PD patients and experimental non-human primate model of PD suggest that the regulation of Rhes mRNA levels by dopaminergic innervation might play a functional role under physiological and pathological conditions.
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